focus -WSS

focus

author：entertainment 2025-10-01 00:05:27 - browse：17

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Bernie Sanders bashes nonprofit hospitals over their tax breaks

WSS

Peter Marks talks Operation Warp Speed for Rare Diseases

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Cancer cells are shown to suck energy source from immune cells

Better Therapeutics data on benefit with GLP

Readout LOUD podcast: Merger Mondays, Ozempic panic

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

explore

focus

Wikipedia

ChatGPT in medicine: STAT answers readers' burning questions

Faced with fears of OxyContin misuse, sales reps touted its safety

Hollywood unions extend contract negotiations for actors

European regulators consider appeal over Amylyx ALS drug

Medical records are filled with copy

The history of OxyContin, told through Purdue Pharma documents

Anesthesiologist group: stop taking Ozempic before surgery

There’s no way to know how good AI health technologies are

Anesthesiologist group: stop taking Ozempic before surgery

How doctors and nurses shape Google's AI

hotspot

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

Kim Kardashian sparks debate on benefits of full

Some of the ways extreme heat will change life as we know it

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Novo acquires Inversago for up to $1 billion

An innovative path out of biotech’s “valley of death”

Wikipedia

focus

knowledge

knowledge